Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1359-1367

  Huang, Vivian W ^a   Prosser, Connie ^a   Kroeker, Karen I ^a   Wang, Haili ^a   Shalapay, Carol ^a   Dhami, Neil ^a   Fedorak, Darryl K ^a   Halloran, Brendan ^a   Dieleman, Levinus A ^a   Goodman, Karen J ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

fecal calprotectin; Infliximab; trough level

Indexed keywords

CALGRANULIN; FECAL CALPROTECTIN; INFLIXIMAB; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; PHARMACOLOGICAL BIOMARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SECONDARY ANALYSIS; ALGORITHM; CHEMISTRY; DRUG MONITORING; FECES; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOMARKERS, PHARMACOLOGICAL; CLINICAL DECISION-MAKING; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LEUKOCYTE L1 ANTIGEN COMPLEX; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; OUTPATIENTS;

EID: 84929936546     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000376     Document Type: Article

References (22)

1. Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
2. Sands B, Anderson F, Bernstein C, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
3. Rutgeerts P, Sandborn W, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
4. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
5. Haens GRDA, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2010;106:199-212.
6. Wright EK, De Cruz P, Gearry R, et al. Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. Inflamm Bowel Dis. 2014; 20:1668-1677.
7. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, c-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
8. Af Björkesten C-G, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528-537.
9. Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756.
10. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
11. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774-781.
12. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666.
13. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919-927.
14. Harvey R, Bradshaw J. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
15. Regueiro M, Loftus E Jr, Steinhart A, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994.
16. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
17. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002:97: 389-396.
18. Jelsness-Jørgensen L-P, Bernklev T, Moum B. Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract. 2013;2013:1-4.
19. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33:987-995.
20. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
21. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447-459.
22. Vos MD, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117.